$HEM, a TSXV-listed biotech firm, emphasizes autologous cell therapies. With 87.12M outstanding shares and a $4.79M market cap, they address significant medical needs in vascular diseases.
#trade #100x #stock #investor #dailytrading #stockMarket #trader $WISA $SXTC $PALI